Zirabev

DRUG2 trials

Conditions

Cervical CancerEpithelial Ovarian CancerFallopian Tube CancerMetastatic Breast CancerMetastatic Colorectal CancerMetastatic Kidney CancerNon Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 2

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Active, not recruitingNCT05601973

ETOP IBCSG Partners FoundationNon Small Cell Lung Cancer

Start: 2023-03-27End: 2026-09-30Target: 60Updated: 2026-01-21

Unknown Phase

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

WithdrawnNCT04889495

PfizerCervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer +5

Start: 2025-05-16End: 2025-08-16Updated: 2025-03-19

Zirabev

Sponsors

Conditions

Phase 2

Unknown Phase